




RealRate

# PHARMACEUTICAL 2021

## Sonoma Pharmaceuticals Inc. Rank 180 of 402





RealRate

# PHARMACEUTICAL 2021

## Sonoma Pharmaceuticals Inc. Rank 180 of 402



The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 140% points. The greatest weakness of Sonoma Pharmaceuticals Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 93% points.

The company's Economic Capital Ratio, given in the ranking table, is 118%, being 70% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	12,383
Cost of Goods Sold	10,603
Intangible Assets	0
Liabilities, Current	4,865
Liabilities, Non-Current	746
Other Assets	1,813
Other Compr. Net Income	0
Other Expenses	137
Other Liabilities	245
Other Net Income	3,862
Other Revenues	18,936
Property and Equipment	365
Research and Development	1,339
Selling, General and Administrative Expense	13,665

Output Variable	Value in 1000 USD
Assets	14,561
Liabilities	5,856
Expenses	25,744
Revenues	18,936
Stockholders Equity	8,705
Net Income	-2,946
Comprehensive Net Income	-2,946
Economic Capital Ratio	118%